We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Core Laboratories to Post Q1 Earnings: Key Metrics to Watch
Read MoreHide Full Article
Key Takeaways
CLB will report Q1 2026 results on April 29, with earnings seen at 6 cents per share on $122.95M revenues.
Core Laboratories cut guidance due to Middle East instability, supply issues and weaker project activity.
CLB faces cost pressures, but resilient Production Enhancement demand may help offset segment weakness.
Core Laboratories Inc. (CLB - Free Report) is set to release first-quarter 2026 results on April 29, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter is pegged at a profit of 6 cents per share on revenues of $122.95 million.
Let us delve into the factors that might have influenced CLB’s performance in the to-be-reported quarter. Before that, it is worth taking a look at the company’s performance in the last reported quarter.
Highlights of Q4 Earnings & Surprise History
In the last reported quarter, the Houston, TX-based oil and gas equipment and services company’s adjusted earnings beat the consensus mark. CLB reported adjusted earnings of 21 cents per share, which was a cent higher than the Zacks Consensus Estimate. Operating revenues of $138.3 million beat the Zacks Consensus Estimate of $132 million. This was attributed to the amplified demand for CLB’s laboratory analytical services and complete diagnostic services in international regions.
CLB’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed the remaining one, delivering an average surprise of 4.9%.
The Zacks Consensus Estimate for first-quarter 2026 earnings has remained unchanged in the past seven days. The estimated figure indicates a 57.1% year-over-year decline. The Zacks Consensus Estimate for revenues also indicates a decline of about 0.5% from the year-ago period’s actual.
Factors to Consider Ahead of CLB’s Q1 Release
Core Laboratories is facing a confluence of near-term headwinds that materially increase the likelihood of an earnings miss in the first quarter of 2026. The company has already revised its guidance downward due to escalating geopolitical instability in the Middle East, which has disrupted client activity through project delays, travel restrictions and supply-chain bottlenecks. Damage to regional oil infrastructure and logistical constraints, particularly around the Strait of Hormuz, have curtailed production and hindered project execution, with Reservoir Description disproportionately impacted due to its reliance on field access and sample movement. Additionally, adverse weather events in North America and Europe further disrupted operations, compounding seasonal weakness typically seen in the first quarter. Tariff-driven cost inflation, rising labor expenses and higher interest costs from new variable-rate debt add margin pressure. The company brought down its total revenue expectations to a range of $119-$123 million from the earlier expected $124-$130 million. Operating income (ex-items) is now expected to range between $5.7 million and $7.1 million. Also, earnings per share (ex-items) are now expected to range between 5 and 7 cents, brought down from the earlier expected 11-15 cents.
Despite near-term disruptions, Core Laboratories retains several levers that could support an earnings beat. Production Enhancement remains relatively resilient, with strong demand for diagnostic services and technological solutions helping offset weakness in other segments. The company’s asset-light model and disciplined cost management could preserve margins better than expected, while mitigation efforts around tariffs and supply chains may ease cost pressures.
What Does Our Model Say About CLB Stock?
Our proven model does not conclusively predict an earnings beat for Core Laboratories this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is not the case here.
CLB’s Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, for this company is 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
CLB’s Zacks Rank: CLB currently carries a Zacks Rank #4 (Sell).
Stocks With the Favorable Combination
Here are some firms from the energy space that you may want to consider, as these have the right combination of elements to post an earnings beat this reporting cycle.
COP is scheduled to release earnings on April 30. Notably, theZacks Consensus Estimate for COP’s 2026 earnings indicates 18.5% year-over-year growth. Valued at around $146.6 billion, COP’s shares have gained 36.6% in a year.
Forum Energy Technologies, Inc. (FET - Free Report) has an Earnings ESP of +4.55% and a Zacks Rank #3 at present. FET is slated to release earnings on April 30.
The Zacks Consensus Estimate for FET’s 2026 earnings indicates 220.6% year-over-year growth.Valued at around $651.2 million, FET’s shares have soared 295% in a year.
Valero Energy Corporation (VLO - Free Report) has an Earnings ESP of +1.83% and a Zacks Rank #1 at present. It is scheduled to release earnings on April 30.
The Zacks Consensus Estimate for VLO’s 2026 earnings indicates 79.4% year-over-year growth.Valued at around $69.8 billion, VLO’s shares have surged 108.1% in a year.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Core Laboratories to Post Q1 Earnings: Key Metrics to Watch
Key Takeaways
Core Laboratories Inc. (CLB - Free Report) is set to release first-quarter 2026 results on April 29, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter is pegged at a profit of 6 cents per share on revenues of $122.95 million.
Let us delve into the factors that might have influenced CLB’s performance in the to-be-reported quarter. Before that, it is worth taking a look at the company’s performance in the last reported quarter.
Highlights of Q4 Earnings & Surprise History
In the last reported quarter, the Houston, TX-based oil and gas equipment and services company’s adjusted earnings beat the consensus mark. CLB reported adjusted earnings of 21 cents per share, which was a cent higher than the Zacks Consensus Estimate. Operating revenues of $138.3 million beat the Zacks Consensus Estimate of $132 million. This was attributed to the amplified demand for CLB’s laboratory analytical services and complete diagnostic services in international regions.
CLB’s earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed the remaining one, delivering an average surprise of 4.9%.
This is depicted in the graph below:
Core Laboratories Inc. Price and EPS Surprise
Core Laboratories Inc. price-eps-surprise | Core Laboratories Inc. Quote
CLB Stock’s Trend in Estimate Revision
The Zacks Consensus Estimate for first-quarter 2026 earnings has remained unchanged in the past seven days. The estimated figure indicates a 57.1% year-over-year decline. The Zacks Consensus Estimate for revenues also indicates a decline of about 0.5% from the year-ago period’s actual.
Factors to Consider Ahead of CLB’s Q1 Release
Core Laboratories is facing a confluence of near-term headwinds that materially increase the likelihood of an earnings miss in the first quarter of 2026. The company has already revised its guidance downward due to escalating geopolitical instability in the Middle East, which has disrupted client activity through project delays, travel restrictions and supply-chain bottlenecks. Damage to regional oil infrastructure and logistical constraints, particularly around the Strait of Hormuz, have curtailed production and hindered project execution, with Reservoir Description disproportionately impacted due to its reliance on field access and sample movement. Additionally, adverse weather events in North America and Europe further disrupted operations, compounding seasonal weakness typically seen in the first quarter. Tariff-driven cost inflation, rising labor expenses and higher interest costs from new variable-rate debt add margin pressure. The company brought down its total revenue expectations to a range of $119-$123 million from the earlier expected $124-$130 million. Operating income (ex-items) is now expected to range between $5.7 million and $7.1 million. Also, earnings per share (ex-items) are now expected to range between 5 and 7 cents, brought down from the earlier expected 11-15 cents.
Despite near-term disruptions, Core Laboratories retains several levers that could support an earnings beat. Production Enhancement remains relatively resilient, with strong demand for diagnostic services and technological solutions helping offset weakness in other segments. The company’s asset-light model and disciplined cost management could preserve margins better than expected, while mitigation efforts around tariffs and supply chains may ease cost pressures.
What Does Our Model Say About CLB Stock?
Our proven model does not conclusively predict an earnings beat for Core Laboratories this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. This is not the case here.
CLB’s Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, for this company is 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
CLB’s Zacks Rank: CLB currently carries a Zacks Rank #4 (Sell).
Stocks With the Favorable Combination
Here are some firms from the energy space that you may want to consider, as these have the right combination of elements to post an earnings beat this reporting cycle.
ConocoPhillips (COP - Free Report) has an Earnings ESP of +8.05% and a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
COP is scheduled to release earnings on April 30. Notably, theZacks Consensus Estimate for COP’s 2026 earnings indicates 18.5% year-over-year growth. Valued at around $146.6 billion, COP’s shares have gained 36.6% in a year.
Forum Energy Technologies, Inc. (FET - Free Report) has an Earnings ESP of +4.55% and a Zacks Rank #3 at present. FET is slated to release earnings on April 30.
The Zacks Consensus Estimate for FET’s 2026 earnings indicates 220.6% year-over-year growth.Valued at around $651.2 million, FET’s shares have soared 295% in a year.
Valero Energy Corporation (VLO - Free Report) has an Earnings ESP of +1.83% and a Zacks Rank #1 at present. It is scheduled to release earnings on April 30.
The Zacks Consensus Estimate for VLO’s 2026 earnings indicates 79.4% year-over-year growth.Valued at around $69.8 billion, VLO’s shares have surged 108.1% in a year.